Recurrent Pterygium
9
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
Digital Colorimetric Scale for Recurrent Pterygium Scar Assessment
Micro-Conjunctival Autografting Combined With Amniotic Membrane Transplantation Treating Recurrent Pterygium Trial
Conjunctival Autograft or Limbal Conjunctival Autograft for Recurrent Pterygium Using Mitomycin C
Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection
Bevacizumab Injection for Recurrent Pterygium
Strategies for Management of Recurrent Pterygium
Recurrent Pterygium Surgery Using Mitomycin C With Limbal Conjunctival or Amniotic Membrane
Clinical Analysis of Recurrence Patterns Following Conjunctival Autografts for Pterygium Surgery
Subconjunctival Bevacizumab and Recurrent Pterygium